Long-term use of Swedish moist snuff and the risk of myocardial infarction amongst men.

Institute of Environmental Medicine, Karolinska Institutet, and Department of Medicine, Karolinska University Hospital, Stockholm, Sweden.
Journal of Internal Medicine (Impact Factor: 6.46). 09/2007; 262(3):351-9. DOI: 10.1111/j.1365-2796.2007.01816.x
Source: PubMed

ABSTRACT The scientific evidence on cardiovascular risks associated with long-term use of snuff is limited and inconclusive. The use of this smokeless tobacco has increased in recent decades, and adverse health effects associated with snuff use could be of great public health concern.
We aimed to study whether long-term use of snuff affects the risk of myocardial infarction.
Between 1978 and 1993 all construction workers in Sweden were offered repeated health check-ups by the Swedish Construction Industry's Organization for Working Environment Safety and Health. A cohort was created with information on tobacco use and other risk factors, collected through questionnaires.
In total, 118,395 nonsmoking men without a history of myocardial infarction were followed through 2004. Information on myocardial infarction morbidity and mortality was obtained from national registers. Relative risk estimates were derived from Cox proportional hazards regression model, with adjustment for age, body mass index and region of residence.
Almost 30% of the men had used snuff. In total, 118 395 nonsmoking men without a history of myocardial infarction were followed through 2004. The multivariable-adjusted relative risks for ever snuff users were 0.91 (95% confidence interval, 0.81-1.02) for nonfatal cases and 1.28 (95% confidence interval, 1.06-1.55) for fatal cases. Heavy users (>or=50 g day(-1)) had a relative risk of fatal myocardial infarction of 1.96 (95% confidence interval, 1.08-3.58). Snuff use increased the probability of mortality from cardiovascular disease amongst nonfatal myocardial infarction patients.
Our results indicate that snuff use is associated with an increased risk of fatal myocardial infarction.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Cigarette companies increasingly promote novel smokeless tobacco products to smokers, encouraging them to use smokeless tobacco in smoke-free environments. New messages may counteract this promotion. We developed 12 initial anti-smokeless message ideas and tested them in eight online focus groups with 75 US smokers. Those smokers who never tried smokeless tobacco were unaware of health risks of novel smokeless tobacco products, perceived scary messages as effective and acknowledged the addictive nature of nicotine. Smokers who had tried smokeless tobacco shared their personal (mainly negative) experiences with smokeless tobacco, were aware of health risks of novel smokeless tobacco products, but denied personal addiction, and misinterpreted or disregarded more threatening messages. Portraying women as smokeless tobacco users was perceived as unbelievable, and emphasizing the lack of appeal of novel smokeless tobacco products was perceived as encouraging continued smoking. Future ads should educate smokers about risks of novel smokeless tobacco products, but past users and never users may require different message strategies.
    Health Education Research 01/2014; · 1.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: An earlier review summarized evidence relating use of snus (Swedish-type moist snuff) to health and to initiation and cessation of smoking. This update considers the effect recent publications on snus use and health have on the overall evidence. The additional evidence extends the list of neoplastic conditions unassociated with snus use (oropharynx, oesophagus, stomach, lung) to include colorectal cancer and acoustic neuroma, and further undermines the weakly-based argument that snus use increases the risk of pancreatic cancer, although there is a report of poorer cancer survival in users. It remains undemonstrated that "snuff-dipper's lesion" increases risk of oral cancer, and recent publications add to the evidence that snus use has no effect on periodontitis or dental caries. Although onset of acute myocardial infarction is not adversely associated with snus use, there is some evidence of an association with reduced survival. Whether this is a direct effect of snus use or a result of confounding by socioeconomic status or other factors requires further investigation, as does a report of an increased risk of heart failure in snus users. Even if some adverse health effects of snus use do exist, it remains clear that they are far less than those of smoking.
    Harm Reduction Journal 12/2013; 10(1):36. · 1.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Snus is a moist smokeless tobacco product with a high nicotine content. Its use has a short-term effect on the cardiovascular system, but the relationship between snus use and stroke is unclear. The aim of this study was to assess the associations between use of snus and incidence of and survival after stroke, both overall and according to subtypes. Pooled analyses of eight Swedish prospective cohort studies were conducted, including 130 485 men who never smoked. We estimated hazard ratios (HRs) with 95% confidence intervals (CIs) of incidence and death after diagnosis using Cox proportional hazard regression models, and case fatality and survival using logistic regression and Kaplan-Meier methods, respectively. No associations were observed between the use of snus and the risk of overall stroke (HR 1.04, 95% CI 0.92-1.17) or of any of the stroke subtypes. The odds ratio (OR) of 28-day case fatality was 1.42 (95% CI 0.99-2.04) among users of snus who had experienced a stroke, and the HR of death during the follow-up period was 1.32 (95% CI 1.08-1.61). Use of snus was not associated with the risk of stroke. Hence, nicotine is unlikely to contribute importantly to the pathophysiology of stroke. However, case fatality was increased in snus users, compared to non-users, but further studies are needed to determine any possible causal mechanisms. This article is protected by copyright. All rights reserved.
    Journal of Internal Medicine 02/2014; · 6.46 Impact Factor